Health Care [ 6/12 ] | Biotechnology [ 33/75 ]
NYSE MKT | Common Stock
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins.
It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder.
The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 14, 25 | -0.39 Increased by +96.61% | - |
| Aug 12, 25 | -0.60 Decreased by -111.25% | -0.35 Decreased by -71.43% |
| May 14, 25 | 2.28 Increased by +914.29% | - |
| Mar 24, 25 | 3.47 Increased by +588.73% | - |
| Nov 13, 24 | -11.52 Decreased by -1.10 K% | -11.52 |
| Aug 13, 24 | 5.34 Increased by +116.73% | -13.68 Increased by +139.00% |
| May 14, 24 | -0.28 Increased by +79.99% | -0.31 Increased by +9.68% |
| Mar 29, 24 | -0.71 Decreased by -468.26% | -0.40 Decreased by -77.50% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by N/A% | -4.54 M Increased by +26.46% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -6.64 M Decreased by -104.05% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | 9.10 M Increased by +107.71% | Increased by +N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | 2.08 M Increased by +107.93% | Increased by +N/A% - |
| Sep 30, 24 | 0.00 Decreased by N/A% | -6.17 M Increased by +98.10% | Decreased by N/A% - |
| Jun 30, 24 | 0.00 Decreased by N/A% | 164.11 M Increased by +1.17 K% | Increased by +N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -118.02 M Decreased by -569.07% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | N/A Decreased by N/A% | -26.24 M Increased by +24.07% | - - |